AI-based Antibody Development Platform

KY-AI^TM is our proprietary artificial intelligence platform for antibody drug development. Built upon the revolutionary alphafold2 algorithm, our specialized software can accurately predict antigen-antibody complex structures and binding affinities with lighting speed, therefore, is able to perform large-scale in silico screening of antibody sequence library generated from NGS to select promising antibody drug candidates against therapeutic targets such as proteins and tumor antigens. Our software is also able to perform affinity maturation by simultaneously substituting multiple amino acid residues to generate novel antibodies with stronger and more specific binding to a therapeutic target. KY-AI^TM greatly speeds up antibody drug development with significantly reduced experimental cost and time.